The Zhitong Finance App learned that on October 17, the China National Drug Administration (NMPA) Drug Evaluation Center (CDE) official website recently announced that the marketing application for injectable sotatercept declared by MSD (MRK.US) was accepted. According to public information, this is a “first-in-class” novel activin signaling inhibitor biologic preparation. The product was approved for marketing by the US FDA in March of this year to treat pulmonary hypertension (PAH). This treatment was previously rated by industry media Evaluate as one of the potentially major treatments in 2024.

The Zhitong Finance App learned that on October 17, the China National Drug Administration (NMPA) Drug Evaluation Center (CDE) official website recently announced that the marketing application for injectable sotatercept declared by MSD (MRK.US) was accepted. According to public information, this is a “first-in-class” novel activin signaling inhibitor biologic preparation. The product was approved for marketing by the US FDA in March of this year to treat pulmonary hypertension (PAH). This treatment was previously rated by industry media Evaluate as one of the potentially major treatments in 2024.